COMPARISON BETWEEN DEXMEDETOMIDINE AND PROPOFOL ON INTERLEUKIN-6 LEVELS IN PATIENTS WITH CHRONIC RHINOSINUSITIS UNDERGOING FUNCTIONAL ENDOSCOPIC SINUS SURGERY

Background: Dexmedetomidine and propofol are expected to serve as intravenous anesthetic agents that reduce inflammatory factors in patients with chronic rhinosinusitis (CRS), particularly those undergoing functional endoscopic sinus surgery (FESS).
Aim: This study aims to compares dexmedetomidine and propofol before and after FESS. Materials and Method: A quasi-experimental, cross-sectional, and analytical study was conducted involving patients with chronic rhinosinusitis (CRS) who underwent elective functional endoscopic sinus surgery (FESS) at Dr. Soetomo General Hospital, Surabaya, Indonesia. CRS patients scheduled for FESS were recruited for this study. Interleukin-6 (IL-6) levels were measured using ELISA 5 minutes after induction and 5 minutes before extubation. The Wilcoxon signed-rank test and Mann-Whitney test were used to determine changes in IL-6 levels before and after the procedure. A total of 24 CRS patients undergoing FESS were included in this study.
Results: The median IL-6 levels in the dexmedetomidine group before and after surgery were 20.24 ng/mL and 34.09
ng/mL, respectively, indicating a significant increase in IL-6 levels (p0.05).
Conclusion: There was a significant change in IL-6 levels in both the dexmedetomidine and propofol groups before and after surgery. However, there was no significant difference between dexmedetomidine and propofol in terms of changes in IL-6 levels among CRS patients undergoing FESS. Further studies are needed to evaluate the economic impact of using dexmedetomidine and propofol as controlled hypotensive agents in FESS procedures.